TECH * Stock Overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-Techne Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,389.66 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.26 |
| 1 Month Change | 0% |
| 3 Month Change | 0.52% |
| 1 Year Change | -16.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| TECH * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -16.4% | 0% | 0% |
Return vs Industry: TECH * underperformed the MX Life Sciences industry which returned -14.6% over the past year.
Return vs Market: TECH * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| TECH * volatility | |
|---|---|
| TECH * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: TECH * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TECH *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 3,000 | Chuck Kummeth | www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Corporation Fundamentals Summary
| TECH * fundamental statistics | |
|---|---|
| Market cap | Mex$213.92b |
| Earnings (TTM) | Mex$4.69b |
| Revenue (TTM) | Mex$19.41b |
45.7x
P/E Ratio11.0x
P/S RatioIs TECH * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECH * income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$357.74m |
| Gross Profit | US$765.87m |
| Other Expenses | US$494.64m |
| Earnings | US$271.23m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.72 |
| Gross Margin | 68.16% |
| Net Profit Margin | 24.14% |
| Debt/Equity Ratio | 19.6% |
How did TECH * perform over the long term?
See historical performance and comparison